Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 336
- Registration Number
- NCT00081484
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1987
- Registration Number
- NCT00009737
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 470
- Registration Number
- NCT00077857
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT00077766
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT00077649
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 673
- Registration Number
- NCT00077610
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 572
- Registration Number
- NCT00077623
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-13
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1469
- Registration Number
- NCT00077636
A Study of Mircera for the Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT00077597
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1886
- Registration Number
- NCT00069121
- Locations
- 🇺🇸
New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
🇺🇸Innovative clinical research institute/American institute of research, Whittier, California, United States
🇺🇸Nh Oncology Hematology, Pa, Hooksett, New Hampshire, United States
© Copyright 2024. All Rights Reserved by MedPath